Establishment of a Yeast Two-Hybrid-Based High-Throughput Screening Model for Selection of SARS-CoV-2 Spike-ACE2 Interaction Inhibitors
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26020678 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Dongsheng Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sci…. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, Spike Glycoprotein, Coronavirus, SARS-CoV-2, High-Throughput Screening Assays. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China, PhD Research Startup Fund of Shanxi Medical University.
Abstract (Originalsprache)
The recent coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has exerted considerable impact on global health. To prepare for rapidly mutating viruses and for the forthcoming pandemic, effective therapies targeting the critical stages of the viral life cycle need to be developed. Viruses are dependent on the interaction between the receptor-binding domain (RBD) of the viral Spike (S) protein (S-RBD) and the angiotensin-converting enzyme 2 (ACE2) receptor to efficiently establish infection and the following replicate. Targeting this interaction provides a promising strategy to inhibit the entry process of the virus, which in turn has both preventive and therapeutic effects. In this study, we developed a robust and straightforward assay based on the Yeast-Two Hybrid system (Y2H) for identifying inhibitors targeting the S-RBD-ACE2 interaction of SARS-CoV-2. Through high-throughput screening, two compounds were identified as potential entry inhibitors. Among them, IMB-1C was superior in terms of pseudovirus entry inhibition and toxicity. It could bind to both ACE2 and S-RBD and induce conformational change in the S-RBD+ACE2 complex. This is the first study to verify the feasibility of utilizing the Y2H system to discover potent SARS-CoV-2 inhibitors targeting the receptor recognition stage. This approach may also be applied in the discovery of other virus receptor recognition inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
- Research Team of Molecular Medicine, The First Clinical Medical School of Shanxi Medical University, Taiyuan 030001, China.
ORCID-Profile: Baoqing You, Zhen Wang
Förderung
- CAMS Innovation Fund for Medical Sciences
- National Natural Science Foundation of China
- PhD Research Startup Fund of Shanxi Medical University
- Provincial Doctoral Fund of Shanxi Medical University
Zitieren
APA
Li, D., You, B., Guo, K., Zhou, W., Li, Y., Wang, C., Chen, X., Wang, Z., Zhang, J., & Si, S. (2025). Establishment of a Yeast Two-Hybrid-Based High-Throughput Screening Model for Selection of SARS-CoV-2 Spike-ACE2 Interaction Inhibitors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26020678
Vancouver
Li D, You B, Guo K, Zhou W, Li Y, Wang C, et al. Establishment of a Yeast Two-Hybrid-Based High-Throughput Screening Model for Selection of SARS-CoV-2 Spike-ACE2 Interaction Inhibitors. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26020678
BibTeX
@article{Li2025,
author = {Li, Dongsheng and You, Baoqing and Guo, Keyu and Zhou, Wenwen and Li, Yan and Wang, Chenyin and Chen, Xiaofang and Wang, Zhen and Zhang, Jing and Si, Shuyi},
title = {Establishment of a Yeast Two-Hybrid-Based High-Throughput Screening Model for Selection of SARS-CoV-2 Spike-ACE2 Interaction Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26020678}
}
EUVIMED